Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00297921
Status:
WITHDRAWN
Last Update Posted:
2013-11-06
First Post:
2006-02-27
Brief Title:
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
Sponsor:
Millennium Pharmaceuticals Inc
Organization:
Millennium Pharmaceuticals Inc
Organization Data
Organization:
Millennium Pharmaceuticals Inc
Class:
INDUSTRY
Study ID:
C03002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Millennium Pharmaceuticals Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None